LSR receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications
View Patent ↗The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.
1. A purified or recombinant Lipolysis Stimulated Receptor, wherein said receptor comprises a polypeptide having at least 90% homology to the polypeptide of SEQ ID NO: 8 and wherein said polypeptide has at least one biological activity selected from the group consisting of fatty acid binding, clathrin binding leptin binding, and lipoprotein binding.
2. A purified or recombinant Lipolysis Stimulated Receptor that a) comprises the amino acid sequence of SEQ ID NO:8; or b) consists of the amino acid sequence of SEQ ID NO:8.
3. The purified or recombinant receptor of claim 2 , wherein said receptor comprises the amino acid sequence of SEQ ID NO:8.
4. The polypeptide of claim 3 , wherein said polypeptide combines with one or more heterologous polypeptides to form an LSR receptor complex, and wherein said complex comprises an α subunit or an α′ subunit, and at least one β subunit.
5. The polypeptide of claim 4 , wherein said complex comprises three β subunits.
6. The polypeptide of claim 4 , wherein said polypeptide is from a human, and wherein said polypeptide has a molecular weight of 64 kD.
7. The polypeptide of claim 4 , wherein said polypeptide is expressed in hepatic cells.
8. The polypeptide of claim 4 , wherein said complex has a biological activity selected from the group consisting of lipoprotein binding, lipoprotein internalization, and lipoprotein degradation.
9. The polypeptide of claim 4 , wherein said complex has a biological activity that is selected from the group consisting of leptin binding, leptin internalization, and leptin degradation.
10. A composition comprising the polypeptide of claim 3 .
11. The composition of claim 10 , further comprising a physiologically acceptable carrier.
12. The purified or recombinant receptor of claim 2 , wherein said receptor consists of the amino acid sequence of SEQ ID NO:8.
13. An isolated or recombinant biologically active polypeptide fragment of SEQ ID NO: 8, said fragment comprising an amino acid sequence selected from the group consisting of:
a) an amino acid sequence spanning amino acids 76 to 94 of SEQ ID NO:8;
b) an amino acid sequence spanning amino acids 76 to 160 of SEQ ID NO:8;
c) an amino acid sequence spanning amino acids 76 to 237 of SEQ ID NO:8;
d) an amino acid sequence spanning amino acids 157 to 249 of SEQ ID NO:8;
e) an amino acid sequence spanning amino acids 236 to 530 of SEQ ID NO:8;
f) an amino acid sequence spanning amino acids 236 to 613 of SEQ ID NO: 8; and
g) an amino acid sequence spanning amino acids 76 to 613 of SEQ ID NO:8.
14. The polypeptide fragment of claim 13 , wherein said polypeptide combines with one or more heterologous polypeptides to form an LSR receptor complex, and wherein said complex comprises an α subunit or an α′ subunit, and at least one β subunit.
15. The polypeptide fragment of claim 14 , wherein said complex comprises three β subunits.
16. The polypeptide fragment of claim 14 , wherein said polypeptide is from a human, and wherein said polypeptide has a molecular weight of 64 kD.
17. The polypeptide fragment of claim 14 , wherein said polypeptide is expressed in hepatic cells.
18. The polypeptide fragment of claim 14 , wherein said complex has a biological activity selected from the group consisting of lipoprotein binding, lipoprotein internalization, and lipoprotein degradation.
19. The polypeptide fragment of claim 14 , wherein said complex has a biological activity that is selected from the group consisting of leptin binding, leptin internalization, and leptin degradation.
20. The polypeptide fragment of claim 13 , wherein said polypeptide is recombinant.
21. A composition comprising the polypeptide of claim 13 .
22. The composition of claim 21 , further comprising a physiologically acceptable carrier.
23. The isolated or recombinant biologically active polypeptide fragment of claim 13 , said fragment comprising an amino acid sequence selected from the group consisting of:
a) an amino acid sequence spanning amino acids 76 to 94 of SEQ ID NO:8 that contains a fatty acid binding site;
b) an amino acid sequence spanning amino acids 76 to 160 of SEQ ID NO:8 that contains a fatty acid binding site and a clathrin binding site;
c) an amino acid sequence spanning amino acids 76 to 237 of SEQ ID NO:8 that contains a fatty acid binding site, a clathrin binding site and contains a transport signal;
d) an amino acid sequence spanning amino acids 157 to 249 of SEQ ID NO:8 that contains a clathrin binding site and contains a transport signal;
e) an amino acid sequence spanning amino acids 236 to 530 of SEQ ID NO:8 and that contains a transport signal, a leptin binding site and a RSRS motif;
f) an amino acid sequence spanning amino acids 236 to 613 of SEQ ID NO: 8 and that contains a transport signal, a leptin binding site, a RSRS motif, and a lipoprotein binding site; and
g) an amino acid sequence spanning amino acids 76 to 613 of SEQ ID NO:8 and that contains a fatty acid binding site, a clathrin binding site, contains a transport signal, contains a leptin binding site, contains an RSRS motif, and has a lipoprotein binding site.